Replies to post #37829 on RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Neuro, >>> two different companies developing a compound for two different indications <<<


But that's the situation we have here -- Samyang advancing CX-1739 for a Neurodegeneration indication, and then Cortex licensing CX-1739 to a different partner for SA/RD or ADHD. Having split ownership of the same compound between two pharmas for different indications seems like something prospective pharma partners would want to avoid.